29786-44-5

Usage

Uses

Used in Organic Synthesis:
1-(4-(trifluoroMethyl)phenyl)cyclobutanecarbonitrile is used as a key intermediate in organic synthesis for its ability to contribute to the formation of complex molecular structures, enhancing the diversity of chemical compounds that can be created.
Used in Pharmaceutical Research:
In pharmaceutical research, 1-(4-(trifluoroMethyl)phenyl)cyclobutanecarbonitrile is utilized as a building block for the development of new drugs, capitalizing on its unique properties to explore novel therapeutic agents.
Used in the Production of Pharmaceuticals:
1-(4-(trifluoroMethyl)phenyl)cyclobutanecarbonitrile is used as an intermediate in the synthesis of various pharmaceuticals, playing a crucial role in the manufacturing process to produce effective medications.
Used in the Production of Agrochemicals:
Similarly, in the agrochemical industry, 1-(4-(trifluoroMethyl)phenyl)cyclobutanecarbonitrile is employed as an intermediate, contributing to the creation of compounds that address agricultural needs such as pest control and crop protection.
Used in Bioactivity and Pharmacological Studies:
1-(4-(trifluoroMethyl)phenyl)cyclobutanecarbonitrile is also used in research to investigate its potential bioactivity and pharmacological properties, with the aim of discovering new applications in medicine and healthcare.

Upstream product

• 109-64-8 1,3-dibromo-propane 
• 2338-75-2 4-(Trifluoromethyl)phenylacetonitrile 

Downstream Products

• 1086379-78-3 1-(4-(trifluoromethyl)phenyl)cyclobutane-1-carboxylic acid 
• 1432492-84-6 2-(hydroxy(1-(4-(trifluoromethyl)phenyl)cyclobutyl)methyl)cyclopentanone 
• 1432050-06-0 (2-aminocyclopentyl){1-[4-(trifluoromethyl)phenyl]cyclobutyl}methanol 
• 29786-32-1 (<1-(α,α,α-Trifluoro-p-tolyl)cyclobutyl>carbonyl)carbamsaeureethylester 
• 29786-23-0 (<1-(α,α,α-Trifluoro-p-tolyl)cyclobutyl>carbonyl)carbamsaeuremethylester 
• 29770-40-9 (<1-(α,α,α-Trifluor-p-tolyl)-cyclobutyl>-carbonyl)-harnstoff 
• 29770-27-2 <1-(α,α,α-Trifluor-p-tolyl)-cyclobutyl>-carbonylisocyanat 
• 29786-54-7 1-(4-(trifluoromethyl)phenyl)cyclobutane-1-carboxamide 

Relevant academic research and scientific papers

Iridium-Catalyzed Enantioselective C(sp3)–H Borylation of Cyclobutanes

We herein report the first example of iridium-catalyzed enantioselective C(sp3)–H borylation of cyclobutanes using benzoxazoline as the directing group. The combination of a chiral bidentate boryl ligand and an iridium precursor has found to effectively catalyze C(sp3)–H borylation to afford a variety of cyclobutylboronates with good to excellent enantioselectivities. We also demonstrate the synthetic utility of the current method by converting the stereogenic C—B bond to other functionalities.

Oxadiazole Amine Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same

The present invention relates to a novel compound having an activity of inhibiting histone deacetylase 6 (HDAC6), an optical isomer thereof or a pharmaceutically acceptable salt thereof, a use thereof for preparation of a drug for treatment, a pharmaceutical composition comprising the same, a treatment method using the composition, and a method for preparing the same. The novel compound, an optical isomer thereof or a pharmaceutically acceptable salt thereof according to the present invention has an activity of inhibiting histone deacetylase 6 (HDAC6), and is effective for preventing or treating HDAC6-related diseases, including infectious diseases; neoplasm; endocrine, nutritional and metabolic diseases; mental and behavior disorders; nerve disorders; eye and adnexa diseases; cardiovascular diseases; respiratory diseases; digestive organ diseases; skin and subcutaneous tissue diseases; musculoskeletal and connective tissue diseases; or congenital malformation, deformation and chromosomal abnormality.COPYRIGHT KIPO 2017

PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS

Disclosed are pyrimidine carboxamide compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2), pharmaceutical compositions and uses thereof.

NOVEL TRPV3 MODULATORS

Disclosed herein are modulators of TRPV3 of formula (II): wherein G1, X1, X2, X3, X4, X5, G2, Ra, Rb, and u are as defined in the specification. Composition

NOVEL TRPV3 MODULATORS

Disclosed herein are modulators of TRPV3 of formula (II): wherein G1, X1, X2, X3, X4, X5, G2, Ra, Rb, and u are as defined in the specification. Composition

NOVEL TRPV3 MODULATORS

Disclosed herein are modulators of TRPV3 of formula (I) wherein G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, u, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

NOVEL TRPV3 MODULATORS

Disclosed herein are modulators of TRPV3 of formula (I), wherein G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, u, and p are as defined in the specifica